MGME1 and Alzheimer disease: In vitro luciferase tests verified the miR‐922 targeting MGME1 regulatory relationship; however, in vivo functional investigations, such as CRISPR‐based knockdown in AD animal models or patient‐derived neurons, are needed to show causality and therapeutic significance.